Cargando…
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
BACKGROUND: The purpose of our study was to develop an online calculator to estimate the effect of docetaxel triplets (DPF) in first line of advanced gastric cancer (AGC), and to assess the external validity of docetaxel trials in individual patients. METHODS: The study includes patients with HER2(-...
Autores principales: | Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Martínez de Castro, Eva, Custodio, Ana, Pericay Pijaume, Carles, Hernandez, Raquel, Aguado, Gema, Castro Unanua, Natalia, Cano, Juana María, López, Flora, Garrido, Marcelo, Fernández Montes, Ana, Visa, Laura, Sánchez Cánovas, Manuel, Limón, María Luisa, Martínez Lago, Nieves, Pimentel, Paola, Hurtado, Alicia, Azkárate, Aitor, Longo, Federico, Diez, Marc, Arias-Martinez, Aranzazu, Sauri, Tamara, Martín Carnicero, Alfonso, Mangas, Monserrat, Martín Richard, Marta, Granja, Mónica, Ramchandani, Avinash, Hernández Pérez, Carolina, Cerdá, Paula, Gil-Negrete, Aitziber, Calvo, Mariona, Vidal Tocino, Rosario, Gallego, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902567/ https://www.ncbi.nlm.nih.gov/pubmed/32970266 http://dx.doi.org/10.1007/s10120-020-01116-x |
Ejemplares similares
-
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
por: Jimenez-Fonseca, Paula, et al.
Publicado: (2021) -
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
por: Jiménez Fonseca, Paula, et al.
Publicado: (2017) -
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
por: Cotes Sanchís, Almudena, et al.
Publicado: (2020) -
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
por: Plazas, J. Gallego, et al.
Publicado: (2022) -
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
por: Jimenez-Fonseca, Paula, et al.
Publicado: (2023)